本帖最后由 老马 于 2012-1-13 21:20 编辑 . n: Z+ q" l8 F% ~) z/ P4 f
" i; e5 a3 v4 @1 ~0 E; q7 u爱必妥和阿瓦斯丁的比较; a l9 I/ u+ V) Q( Q
9 E* D5 u/ o @+ L: d; n9 P* U% F
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/% J% Q( n- l5 H. p# A. J) f) R
$ y4 e7 S% B% Q( d" M1 l& x+ O
7 I# S5 D$ K! [5 S4 U$ q4 b: k
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/* t- r3 |6 s+ p$ w0 D
==================================================7 R9 J9 M7 u" h; o, j* @
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)# s# L8 t; n) Z! F* U& k& x' Z
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.% R v4 Y5 k3 {* C' W" s
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
. k) `* y% D# ^2 R- T8 v' f, o
|